The Rayne Institute, School of Cancer & Pharmaceutical Sciences, King's College London, London, United Kingdom.
Department of Biomedicine, Neuroscience and Advanced Diagnostic, Laboratory of Immunopathology and Immunosenescence, University of Palermo, Palermo, Italy.
Curr Pharm Des. 2019;25(39):4163-4167. doi: 10.2174/1381612825666191111155800.
Aging is characterized by a general decline in a range of physiological functions, with a consequent increase in the risk of developing a variety of chronic diseases and geriatric syndromes. Additionally, increasing age is accompanied by a progressive decline in both innate and acquired immune system, referred to as immunosenescence. This impaired ability to mount an efficient immune response after exposure to microorganisms or vaccines represents a major challenge in acquiring protection against pathogens in aging. Therefore, there is still a great need for vaccines that are tailored to optimally stimulate the aged immune system, thus promoting more successful aging. Various strategies can be used to improve vaccine efficacy in old people. Despite this, metaanalyses have clearly shown that the magnitude of protection obtained remains lower in older adults. Recent studies show that stimulation of Toll-like receptors, using stimulatory ligands, can enhance vaccine efficacy by a number of mechanisms, including the activation of innate immune cells and the consequent production of inflammatory cytokines. Therefore, a possible strategy for more effective vaccination in the older population is the triggering of multiple TLRs, using a combined adjuvant for the synergistic activation of cellular immunity. Preliminary in vitro data suggest that in humans the presence of multiple TLR agonists can result in the greater stimulation of antigen-specific immune responses in immune cells both in the young healthy and in the immune senescent older donors. These data suggest that appropriately selected combinations of TLR agonists could enhance the efficacy of vaccination mediated immunity in older people.
衰老是指一系列生理功能的普遍下降,随之而来的是各种慢性疾病和老年综合征风险的增加。此外,随着年龄的增长,先天和获得性免疫系统都会逐渐衰退,这被称为免疫衰老。这种在接触微生物或疫苗后产生有效免疫反应的能力受损,是在衰老人群中获得针对病原体的保护的主要挑战。因此,仍然需要针对老年人优化的免疫刺激的疫苗,从而促进更成功的衰老。可以使用各种策略来提高老年人疫苗的效力。尽管如此,荟萃分析清楚地表明,在老年人中获得的保护程度仍然较低。最近的研究表明,使用刺激配体刺激 Toll 样受体可以通过多种机制增强疫苗的效力,包括激活先天免疫细胞和随后产生炎症细胞因子。因此,针对老年人群更有效的疫苗接种的一种可能策略是使用联合佐剂触发多个 TLR,以协同激活细胞免疫。初步的体外数据表明,在人类中,多种 TLR 激动剂的存在可以导致年轻健康和免疫衰老的老年供体的免疫细胞中针对抗原特异性免疫反应的更大刺激。这些数据表明,适当选择的 TLR 激动剂组合可以增强老年人疫苗介导免疫的效力。